Vascular priming enhances chemotherapeutic efficacy against head and neck cancer

Oral Oncology

Volumn 49, Issue 9, 2013, Pages 893-902

  Folaron, Margaret ^a   Kalmuk, James ^a   Lockwood, Jaimee ^a   Frangou, Costakis ^a   Vokes, Jordan ^a   Turowski, Steven G ^a   Merzianu, Mihai ^a   Rigual, Nestor R ^a   Sullivan Nasca, Maureen ^a   Kuriakose, Moni A ^a   Hicks, Wesley L ^a   Singh, Anurag K ^a   Seshadri, Mukund ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Head and neck squamous cell carcinoma; Vascular disrupting agents; Vascular targeting

Indexed keywords

DOCETAXEL; DOXORUBICIN; GADOLINIUM PENTETATE MEGLUMINE; IRINOTECAN; VADIMEZAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CANCER CHEMOTHERAPY; CANCER MODEL; CANCER SURVIVAL; CELL KILLING; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; FLUORESCENCE MICROSCOPY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANGIOGENESIS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; VASCULAR DISRUPTING AGENTS; VASCULAR TARGETING;

ANTINEOPLASTIC AGENTS; HEAD AND NECK NEOPLASMS; HUMANS; MAGNETIC RESONANCE IMAGING; MICROSCOPY, FLUORESCENCE; XANTHONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883135592     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2013.06.011     Document Type: Article

References (50)

1. S.G. Patel, and J.P. Shah TNM staging of cancers of the head and neck: striving for uniformity among diversity CA Cancer J Clin 55 2005 242 248
2. P. Blanchard, B. Baujat, V. Holostenco, A. Bourredjem, C. Baey, and J. Bourhis Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site Radiother Oncol 100 2011 33 40
3. J. Folkman Tumor angiogenesis: therapeutic implications N Engl J Med 285 1971 1182 1186 November 18
4. U.K. Zätterström, E. Brun, R. Willén, E. Kjellén, and J. Wennerberg Tumor angiogenesis and prognosis in squamous cell carcinoma of the head and neck Head Neck 17 1995 312 318
5. F.C. Galmarini, C.M. Galmarini, M.I. Sarchi, J. Abulafia, and D. Galmirini Heterogeneous distribution of tumor blood supply affects the response to chemotherapy in patients with head and neck cancer Microcirculation 7 2000 405 410
6. J.H. Kaanders, K.I. Wijffels, H.A. Marres, A.S. Ljungkvist, L.A. Pop, and F.J. van den Hoogen Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer Cancer Res 62 2002 7066 7074
7. B.C. Baguley, and L.M. Ching DMXAA: an antivascular agent with multiple host responses Int J Radiat Oncol Biol Phys 54 2002 1503 1511
8. M. Seshadri, R. Mazurchuk, J.A. Spernyak, A. Bhattacharya, Y.M. Rustum, and D.A. Bellnier Activity of the vascular-disrupting agent 5,6- dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts Neoplasia 8 2006 534 542
9. M. Seshadri, N.T. Sacadura, and T. Coulthard Monitoring antivascular therapy in head and neck cancer xenografts using contrast-enhanced MR and US imaging Angiogenesis 14 2011 491 501
10. R. Pili, M.A. Rosenthal, P.N. Mainwaring, G. Van Hazel, S. Srinivas, and R. Dreicer Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC Clin Cancer Res 16 2010 2906 2914
11. P.N. Lara Jr, J.Y. Douillard, K. Nakagawa, J. von Pawel, M.J. McKeage, and I. Albert Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer J Clin Oncol 29 2011 2965 2971
12. G.M. Tozer, C. Kanthou, and B.C. Baguley Disrupting tumour blood vessels Nat Rev Cancer 5 2005 423 435 [Review]
13. B.C. Baguley, and D.W. Siemann Temporal aspects of the action of ASA404 (Vadimezan; DMXAA) Expert Opin Investig Drugs 19 2010 1413 1425
14. M. Seshadri, J.A. Spernyak, R. Mazurchuk, S.H. Camacho, A.R. Oseroff, and R.T. Cheney Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy Clin Cancer Res 11 2005 4241 4250
15. L. Zhao, L.M. Ching, P. Kestell, L.R. Kelland, and B.C. Baguley Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): increased tumor vascular permeability Int J Cancer 116 2005 322 326
16. M. Seshadri, J.A. Spernyak, P.G. Maiery, R.T. Cheney, R. Mazurchuk, and D.A. Bellnier Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome Neoplasia 9 2007 128 135
17. M. Seshadri, M. Merzianu, H. Tang, N.R. Rigual, M. Sullivan, and T.R. Loree Establishment and characterization of patient tumor-derived head and neck squamous cell carcinoma xenografts Cancer Biol Ther 8 2009 2275 2283
18. A. Bhattacharya, M. Seshadri, S.D. Oven, K. Tóth, M.M. Vaughan, and Y.M. Rustum Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs Clin Cancer Res 14 2008 3926 3932
19. R.C. Orth, J. Bankson, R. Price, and E.F. Jackson Comparison of single- and dual-tracer pharmacokinetic modeling of dynamic contrast-enhanced MRI data using low, medium, and high molecular weight contrast agents Magn Reson Med 58 2007 705 716
20. M. Singh, A. Lima, R. Molina, P. Hamilton, A.C. Clermont, and V. Devasthali Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models Nat Biotechnol 28 2010 585 593
21. R.C. Gentleman, V.J. Carey, D.M. Bates, B. Bolstad, M. Dettling, and S. Dudoit Bioconductor: open software development for computational biology and bioinformatics Genome Biol 5 2004 R80
22. P. Du, W.A. Kibbe, and S.M. Lin Lumi: a pipeline for processing Illumina microarray Bioinformatics 24 2008 1547 1548
23. D. Merico, R. Isserlin, O. Stueker, A. Emili, and G.D. Bader Enrichment map: a network-based method for gene-set enrichment visualization and interpretation PLoS ONE 5 2010 e13984
24. H. Mi, N. Guo, A. Kejariwal, and P.D. Thomas PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathways Nucleic Acids Res 35 2007 D247 D252
25. A.J. Primeau, A. Rendon, D. Hedley, L. Lilge, and I.F. Tannock The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors Clin Cancer Res 11 2005 8782 8788
26. J.B. Vermorken, E. Remenar, C. van Herpen, T. Gorlia, R. Mesia, and M. Degardin Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer N Engl J Med 357 2007 1695 1704
27. R.P. Mason, D. Zhao, L. Liu, M.L. Trawick, and K.G. Pinney A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment Integr Biol (Camb) 3 2011 375 387
28. L.C. Wang, L. Thomsen, R. Sutherland, C.B. Reddy, S.M. Tijono, and C.J. Chen Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404) Neoplasia 11 2009 793 803
29. J. Sun, L.C. Wang, Z.G. Fridlender, V. Kapoor, G. Cheng, and L.M. Ching Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4- acetic acid (DMXAA) plays an important role in macrophage stimulation Biochem Pharmacol 82 2011 1175 1185
30. K. Henare, L. Wang, L.C. Wang, L. Thomsen, S. Tijono, and C.J. Chen Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA Br J Cancer 106 2012 1134 1147
31. E. Ruoslahti Specialization of tumour vasculature Nat Rev Cancer 2 2002 83 90 [Review]
32. D.W. Siemann The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents Cancer Treat Rev 37 2011 63 74
33. T. Marysael, Y. Ni, E. Lerut, and P. de Witte Influence of the vascular damaging agents DMXAA and ZD6126 on hypericin distribution and accumulation in RIF-1 tumors J Cancer Res Clin Oncol 137 2011 1619 1627
34. B.G. Siim, A.E. Lee, S. Shalal-Zwain, F.B. Pruijn, M.J. McKeage, and W.R. Wilson Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) Cancer Chemother Pharmacol 51 2003 43 52
35. M. McKeage, and L. Kelland 5,6-Dimethylxanthenone-4-acetic acid (DMXAA): clinical potential in combination with taxane-Based chemotherapy Am J Cancer 5 2006 155 162
36. C.J. Lash, A.E. Li, M. Rutland, B.C. Baguley, L.J. Zwi, and W.R. Wilson Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs Br J Cancer 78 1998 439
37. D.W. Siemann, E. Mercer, S. Lepler, and A.M. Rojiani Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy Int J Cancer 99 2002 1 6
38. M. Martinelli, K. Bonezzi, E. Riccardi, E. Kuhn, R. Frapolli, and M. Zucchetti Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel Br J Cancer 97 2007 888 894
39. J.L. Gevertz Computational modeling of tumor response to vascular-targeting therapies - part I: validation Comput Math Methods Med 2011 830515
40. A. Bagri, L. Berry, B. Gunter, M. Singh, I. Kasman, and L.A. Damico Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy Clin Cancer Res 16 2010 3887 3900
41. Y. Shaked, A. Ciarrocchi, M. Franco, C.R. Lee, S. Man, and A.M. Cheung Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors Science 313 2006 1785 1787
42. A.F. Welford, D. Biziato, S.B. Coffelt, S. Nucera, M. Fisher, and F. Pucci TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice J Clin Invest 121 2011 1969 1973
43. G.U. Dachs, A.J. Steele, C. Coralli, C. Kanthou, A.C. Brooks, and S.P. Gunningham Anti-vascular agent combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression BMC Cancer 7 2006 280
44. M. Taylor, F. Billiot, V. Marty, V. Rouffiac, P. Cohen, and E. Tournay Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells Cancer Discov 2 2012 434 449
45. B.A. Murphy, A. Cmelak, B. Burkey, J. Netterville, Y. Shyr, and S. Douglas Topoisomerase I inhibitors in the treatment of head and neck cancer Oncology (Williston Park) 15 2001 47 52
46. M.R. Posner, D.M. Hershock, C.R. Blajman, E. Mickiewicz, E. Winquist, and V. Gorbounova Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer N Engl J Med 357 2007 1705 1715
47. S.C. Yeung, M. She, H. Yang, J. Pan, L. Sun, and D. Chaplin Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model J Clin Endocrinol Metab 92 2007 2902 2909
48. G. Taraboletti, G. Micheletti, R. Dossi, P. Borsotti, M. Martinelli, and F. Fiordaliso Potential antagonism of tubulin-binding anticancer agents in combination therapies Clin Cancer Res 11 2005 2720 2726
49. M.B. Jameson, and M. Head Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA) Expert Opin Drug Metab Toxicol 7 2011 1315 1326
50. C. Clémenson, E. Jouannot, A. Merino-Trigo, C. Rubin-Carrez, and E. Deutsch The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models Invest New Drugs 31 2 2013 273 284